

DAFTAR PUSTAKA

1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE Official Report: A practical clinical definition of epilepsy. *Epilepsia*. 2014;55(4):475–82.
2. Fiest KM, Sauro KM, Wiebe S, Patten SB, Dykeman J, Pringsheim T, et al. Prevalence and incidence of epilepsy. *Neurology*. 2017;(88):296–303.
3. World Health Organization. *Epilepsy: a public health imperative*. Vol. 1. 2019.
4. Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. *Neurology*. 2012;78(20):1548–54.
5. Meyer AC, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: A systematic review. *Bull World Health Organ*. 2010;88(4):260–6.
6. Muttaqin Z. Epilepsy surgery in Indonesia: Achieving better result with limited resources. *Medica Hosp J Clin Med*. 2019;1(1):1–6.
7. Lowenstein DH. Seizures and epilepsy. In: Kasper DL, Fauci AS, Hauser S, Jameson JL, Longo DL, Loscalzo J, editors. *Harrison's neurology in clinical medicine*, 4th ed. New York: The McGraw-Hill Companies, Inc; 2017 [cited 2021 Feb 8]
8. Sureka RK. Clinical profile and spectrum of epilepsy in rural Rajasthan. *J Assoc Physicians India*. 1999 Jun;47(6):608-10. PMID: 10999158
9. Da Mota Gomes M, De Souza Maia Filho H, Noé RAM. Anti-epileptic drug intake adherence: The value of the blood drug level measurement and the clinical approach. *Arq Neuropsiquiatr*. 1998;56(4):708–13.
10. World Health Organization. *Adherence to long-term therapies: evidence for action*. 2003. [Cited 2021 Feb 8] Available from: https://www.who.int/chp/knowledge/publications/adherence_report/en/
11. Chandra RS, Dalvi SS, Karnad PD, Kshirsagar NA, Shah PU. Compliance monitoring in epileptic patients. *J Assoc Physicians India*. 1993 Jul;41(7):431-2. PMID: 8300489.
12. French J. The long-term therapeutic management of epilepsy. *Ann Intern Med*. 1994;120(5):411–22.
13. Mawuntu AHP, Khosama H, Mahama CN, Sekeon SAS, Winifred K. Anti-epileptic drugs adherence of epilepsy patients in Indonesia. *Int J Community Med Public Heal*. 2020;7(6):2082.
14. Permatananda PAN, Budi Apsari PI, Harkitasari S. Medication Adherence and Quality of Life Among Epilepsy Patients: a Cross Sectional Study. *Int J Res -GRANTHAALAYAH* [Internet]. 2019;7(3):1–10. Available from: <http://dx.doi.org/10.29121/granthaalayah.v7.i3.2019.937>
15. Kementerian Kesehatan. *Hindari lansia dari covid-19*. [Cited 2021 Feb 8] Available from: <http://www.padk.kemkes.go.id/article/read/2020/04/23/21/hindari-lansia->

dari-covid-19.html

16. Nugraha B, Wahyuni LK, Laswati H, Kusumastuti P, Tulaar AB, Gutenbrunner C. COVID-19 pandemic in Indonesia: Situation and challenges of rehabilitation medicine in Indonesia. *Acta Med Indones*. 2020;52(3):299–305.
17. French JA, Brodie MJ, Caraballo R, Devinsky O, Ding D, Jehi L, et al. Keeping people with epilepsy safe during the COVID-19 pandemic. *Neurology*. 2020;94(23):1032–7.
18. Fonseca E, Quintana M, Lallana S, Luis Restrepo J, Abraira L, Santamarina E, et al. Epilepsy in time of COVID-19: A survey-based study. *Acta Neurol Scand*. 2020;142(6):545–54.
19. Bromfield EB, Cavazos JE, Sirven JI, editors. An introduction to epilepsy [Internet]. West Hartford (CT): American Epilepsy Society; 2006. Chapter 3, Neuropharmacology of Antiepileptic Drugs. [Cited 2021 Feb 8] Available from: <https://www.ncbi.nlm.nih.gov/books/NBK2513/>
20. Devinsky O. Patients with refractory seizures. *N Engl J Med*. 1999;340:1565–70.
21. Kassahun G, Moges G, Demessie Y. Assessment of patients' adherence to antiepileptic medications at dessie referral hospital, chronic follow-up, south wollo, amhara region, north east Ethiopia. *Neurol Res Int*. 2018;2018.
22. Leppik IE. How to get patients with epilepsy to take their medication. The problem of noncompliance. *Postgrad Med*. 1990;88(1):253–6.
23. Brigo F, Bonavita S, Leocani L, Tedeschi G, Lavorgna L. Telemedicine and the challenge of epilepsy management at the time of COVID-19 pandemic. *Epilepsy Behav* [Internet]. 2020;110:107164. Available from: <https://doi.org/10.1016/j.yebeh.2020.107164>
24. Hernando-Requejo V, Huertas-González N, Lapeña-Motilva J, Ogando-Durán G. The epilepsy unit during the COVID-19 epidemic: The role of telemedicine and the effects of confinement on patients with epilepsy. *Neurologia*. 2020;35(4):274–6.
25. Lai SL, Hsu MT, Chen SS. The impact of SARS on epilepsy: The experience of drug withdrawal in epileptic patients. *Seizure*. 2005;14(8):557–61.
26. Mueller TM, Kostev K, Gollwitzer S, Lang JD, Stritzelberger J, Westermayer V, et al. The impact of the coronavirus disease (COVID-19) pandemic on outpatient epilepsy care: An analysis of physician practices in Germany. *Epilepsy Behav* [Internet]. 2021;117:107833. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33618316>
27. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):512–21.

28. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. *Med Pharm Reports*. 2019;92(2):117–22.
29. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: Its importance in cardiovascular outcomes. *Circulation*. 2009;119(23):3028–35.
30. Novak V. Epilepsy Treatment Introduction. *Clin Ther*. 2017;39(8):e105–6.
31. Kim KT, Kim DW, Yang KI, Lee ST, Byun JI, Seo JG, et al. Refining general principles of antiepileptic drug treatments for epilepsy. *J Clin Neurol*. 2020;16(3):383–9.
32. Sperling MR, Feldman H, Kinman J, Liporace JD, O'Connor MJ. Seizure control and mortality in epilepsy. *Ann Neurol*. 1999;46(1):45–50.
33. McWilliam M, Al Khalili Y. Idiopathic Generalized Epilepsy. [Updated 2021 Jul 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK546611/>
34. Weinstein S. Seizures and epilepsy: An overview. *Epilepsy Intersect Neurosci Biol Math Eng Phys*. 2016;65–77.
35. World Health Organization. Epilepsy. 2019. [Cited 2021 Oct 11] Available from: <https://www.who.int/news-room/fact-sheets/detail/epilepsy>
36. Ernawati I, Islamiyah WR, Sumarno. How to improve clinical outcome of epileptic seizure control based on medication adherence? A literature review. *Open Access Maced J Med Sci*. 2018;6(6):1174–9.
37. O'Rourke G, O'Brien JJ. Identifying the barriers to antiepileptic drug adherence among adults with epilepsy. *Seizure* [Internet]. 2017;45:160–8. Available from: <http://dx.doi.org/10.1016/j.seizure.2016.12.006>
38. Paschal AM, Hawley SR, Romain TS, Ablah E. Measures of adherence to epilepsy treatment: Review of present practices and recommendations for future directions. *Epilepsia*. 2008;49(7):1115–22.
39. De las Cuevas C, Peñate W. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting. *Int J Clin Heal Psychol*. 2015;15(2):121–9.
40. Yang A, Wang B, Zhu G, Jiao Z, Fang Y, Tang F, et al. Validation of Chinese version of the Morisky medication adherence scale in patients with epilepsy. *Seizure* [Internet]. 2014;23(4):295–9. Available from: <http://dx.doi.org/10.1016/j.seizure.2014.01.003>
41. Sander JW. The use of antiepileptic drugs - Principles and practice. *Epilepsia*. 2004;45(SUPPL. 6):28–34.
42. World Health Organization. Who Director-General's opening remarks at the media briefing on COVID-10 - 11 March 2020. 2020. [Cited 2021 Jul 8] Available from: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19--->

11-march-2020

43. Ryan RE, Parkhill A, Schonfeld L, Walsh L, Lowe D, Al. E. WHO: What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control? 2021.
44. Kalogianni A. Factors affect in patient adherence to medication regimen. *Heal Sci J.* 2011;5(3):157–8.
45. Beghi E. The Epidemiology of Epilepsy. *Neuroepidemiology.* 2020;54(2):185–91.
46. Albert DVF, Das RR, Acharya JN, Lee JW, Pollard JR, Punia V, et al. The Impact of COVID-19 on Epilepsy Care: A Survey of the American Epilepsy Society Membership. *Epilepsy Curr.* 2020;20(5):316–24.
47. Mostacci B, Licchetta L, Cacciavillani C, Di Vito L, Ferri L, Menghi V, et al. The Impact of the COVID-19 Pandemic on People With Epilepsy. An Italian Survey and a Global Perspective. *Front Neurol.* 2020;11(December):1–9.
48. Assenza G, Lanzone J, Brigo F, Coppola A, Di Gennaro G, Di Lazzaro V, et al. Epilepsy Care in the Time of COVID-19 Pandemic in Italy: Risk Factors for Seizure Worsening. *Front Neurol.* 2020;11(July):1–11.
49. Cross JH, Kwon CS, Asadi-Pooya AA, Balagura G, Gómez-Iglesias P, Guekht A, et al. Epilepsy care during the COVID-19 pandemic. *Epilepsia.* 2021;62(10):2322–32.
50. Lai SL, Hsu MT, Chen SS. The impact of SARS on epilepsy: The experience of drug withdrawal in epileptic patients. *Seizure.* 2005;14(8):557–61.
51. Rathore C, Baheti N, Ram A, Afshan S. Impact of COVID-19 pandemic on epilepsy practice in India : A tripartite survey. 2020;(January).